| Cat. No. |
Product Name |
Information |
| PC-62992 |
Aplaviroc hydrochloride
|
Aplaviroc (GSK-873140. |
| PC-62990 |
Elubrixin tosylate
|
Elubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist. |
| PC-62775 |
CXCR2-IN-68
|
CXCR2-IN-68 is a potent, selective, brain penetrant, and orally bioavailable CXCR2 antagonist with pIC50 of 9.0, displays 730-fold selectivity over CXCR1 and >1,900-fold selectivity over all other chemokine receptors. |
| PC-61983 |
C-021 dihydrochloride
|
C-021 dihydrochloride is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively.. |
| PC-61982 |
CCX-6239
|
CCX-6239 is a novel potent, orally available CCR4 inhibitor with potential utility in the treatment of allergic airways disease.. |
| PC-61980 |
GSK-2239633
|
GSK-2239633 is a potent, selective, allosteric CCR4 antagonist with pIC50 of 7.96. |
| PC-61559 |
PF-04634817 succinate
|
PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema. . |
| PC-61475 |
Ladarixin sodium
|
A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM. |
| PC-61301 |
ALT-1188
|
A novel potent, nonpeptide CXCR4 antagonist with IC50 of 0.93 nM. |
| PC-61291 |
POL2438
|
A highly potent, selective beta-hairpin mimetic CXCR4 inhibitor with IC50 of 1.9 nM in Ca2+ flux assay. |
| PC-61290 |
POL3026
|
A highly potent, selective beta-hairpin mimetic CXCR4 inhibitor with IC50 of 1.2 nM in Ca2+ flux assay. |
| PC-61289 |
POL5551
|
A novel peptidic, potent and highly selective CXCR4 antagonist with IC50 of 1.7 nM. |
